Healthcare >> CEO Interviews >> November 2, 2009
DR. ROBIN L. SMITH joined NeoStem as Chairman of its advisory board in September 2005, later becoming the Chief Executive Officer and Chairman of the board on June 2, 2006 Dr. Smith, who received a medical degree from Yale University in 1992 and a master's degree in business administration from the Wharton School in 1997, brings to the company extensive experience in medical enterprises and business development. From 2000 to 2003, Dr. Smith served as President and Chief Executive Officer of IP2M, a multi-platform media company that specializes in health care. During her term the company was selected as being one of the 10 fastest-growing technology companies in Houston. IP2M was sold to a publicly traded company in February 2003. Dr. Smith served on the board of directors of two privately held companies, Talon Air and Biomega, and also served on the Chemotherapy Foundation Board of Trustees and The New York Theatre Ballet. She currently serves on the board of trustees of the NYU Medical Center Board, is Chairman of the board of directors for the New York University Hospital for Joint Diseases, where she heads up new development efforts and board member recruitment, and serves on the board of Choose Living. Dr. Smith is the President and serves on the board of directors of The Stem for Life Foundation. She was originally appointed to the board of directors in June 2006 pursuant to the terms of the Securities Purchase Agreement in the June 2006 private placement. Profile
TWST: Would you begin with an introduction to NeoStem and a description of the company, the business and the organization?
Dr. Smith: NeoStem (NBS)is an American Stock Exchange company. The Symbol is
